A 15.6% margin quarter, an 18% full-year guide, and a Catalysts recovery that has to show up in twelve weeks
CLN.SW · Earnings Call · 2026-11-03
The Miss and the Promise
Clariant's third quarter was two different quarters stapled together. On the top line it was strong: sales of CHF 968 million, up 5.6% in local currency and 6.7% excluding portfolio pruning, with value-based pricing up 5.7% and positive in all three business units. Pricing did the heavy lifting against 12% higher raw materials, 9% higher energy and 24% higher logistics costs.
On the bottom line it was a miss. EBITDA before exceptionals fell 6.5% to CHF 151.5 million, a 15.6% margin against 17.9% a year earlier. Conrad Keijzer was unusually explicit about the composition: about 100 basis points from the phasing of provisions in corporate costs, and about 100 basis points from volatile raw materials hitting the cost and valuation of inventory in Care Chemicals and Catalysts.
That inventory mechanism is the most under-appreciated part of the story. In the second quarter, Care Chemicals margins rose roughly 300 basis points on a positive inventory revaluation. In the third quarter the same mechanism reversed. Management's line — that the underlying pricing is intact and formula-based pass-through simply lags — is plausible, but it means reported divisional margins are currently a poor read on the underlying business. The CFO's arithmetic on the nine-month view — Care Chemicals margins up 30 basis points year-to-date — is the better anchor than the quarterly print.
Which brings us to the arithmetic that dominated the Q&A. Year-to-date group margin is 17.1%. The full-year guide is still around 18% — which requires something near 21% in the fourth quarter. Chetan Udeshi of JPMorgan put the tension more bluntly than any sell-side note could:
It's quite unusual for a company to miss and say, Q4 is actually looking great after missing Q3.
Keijzer's answer leaned on the order book and on October: all business units up year-on-year in revenue, a Catalysts book above last year with a better mix, and the observation that “the year-to-date EBITDA margin is running at 17.1%. So it is built on a strong Q4 that we see in the order books” — Conrad Keijzer, CEO · 2026-11-03. The honest read is that this is a company asking the market to underwrite one quarter of execution after nine months of drift. Notably, this is the second consecutive year where the fourth quarter carries the guide — the same shape of promise appeared in the October 2025 call.
The Middle East Is Specifically a Catalysts Problem
The Middle East conflict is not a new theme here — it has been threaded through every call since the spring. What is new is that management has finally quantified how concentrated the damage is. Catalysts volumes fell 1.9% and divisional EBITDA dropped 29.4% to CHF 23.1 million, a 13.3% margin versus 19.1%. Keijzer then gave the number that explains the whole group miss:
“roughly 15% of our revenue in Catalysts sits in the Middle East... heavily skewed towards petrochemicals as well as Syngas. So it's basically CATOFIN and Syngas. And these are, as you would expect, the higher-margin products in our portfolio.” — Conrad Keijzer, CEO · 2026-11-03
So the group's margin problem is a mix problem concentrated in a single high-margin geography. The force majeure count has been the running gauge: 88 in the first quarter, well above 100 by mid-year, and now still above 100 globally — but easing outside the Middle East as Chinese, Japanese and Korean customers re-source feedstock. That easing is the entire basis for the Q4 recovery argument, and it has been the basis for two quarters running (“we were actually at a number well above 100 force majeures globally in the sector” — Conrad Keijzer, CEO · 2026-07-31, July 2026). Each quarter the number stays elevated but the explanation for the recovery stays the same. At some point a repeated catalyst for recovery becomes a reason to discount it.
The genuinely forward-looking item buried in the Q&A is a new-build win: “the biggest CATOFIN project so far, a 1.2 million tonnes CATOFIN line in China” — Conrad Keijzer, CEO · 2026-11-03 with Zhejiang Petrochemicals, landing in revenue around 2027-28. Add the observation that customers are delaying turnarounds because Middle East volumes are being absorbed in the US and Europe, and you get a plausible new build and refill recovery — but in 2027, not in this year's fourth quarter.
Ashland, and the Discipline Reflex
Three analysts asked about M&A, and none of them were asking hypothetically. Keijzer would not comment on rumours, but the prior-call record matters: in July he was explicit that “There's not many out there. We haven't missed any, I think, in this segment” — Conrad Keijzer, CEO · 2026-07-31 — an answer that reads very differently now that press reports link Clariant to Ashland alongside a private equity partner.
The script that follows is disciplined and repeated near-verbatim: organic growth first, bolt-on acquisitions second, “We have a quality ambition, not a size ambition.” — Conrad Keijzer, CEO · 2026-11-03 The investment grade rating is cited as a hard constraint on any deal structure. That is a coherent framework — but it is the same framework that was used to describe Lucas Meyer-sized transactions, and an Ashland-scale deal is not that. Note also that the medium-term revenue guide of 4-6% local currency growth is explicit in its dependence on a market growing 2-4%. In a year when the chemical industry is contracting 0.6%, that gap is the reason bolt-ons keep coming up. The tension between the stated strategy and the reported news flow is the single most consequential open question on this equity.
What Is Not Being Talked About
The absence of certain themes is as informative as their presence. The market's dominant chemical-sector obsessions this year have been tariffs and tariff refunds — IEEPA, USMCA, reciprocal duties. Clariant sidesteps it almost entirely: “we have 68 factories globally. So tariffs for us are not a significant impact on our results. We produce by and large, in a region for a region.” — Conrad Keijzer, CEO · 2026-11-03 That is a genuine structural advantage in a year when tariff noise has been the top global keyword theme across the entire reporting universe.
The Shell case has also gone quiet. A quarter ago it dominated the Q&A, described as “a big step forward for the company” — Conrad Keijzer, CEO · 2026-07-31 after the Amsterdam District Court dismissed the ethylene claims. Today it is a single sentence — an appeal has been filed, procedural hearings next year, no news. With no provision taken and no read-across resolved, the overhang is not gone; it is simply unpriced in the conversation.
What has replaced it is a newer, more political register: unfair competition, Cefic board discussions, calls for the EU to step up anti-dumping measures, and the uncomfortable asymmetry that European product still faces roughly a 12.5% tariff into the US while gas costs are ten-to-twelve times higher in Europe than America. For a company that has spent five years repositioning itself out of commodity chemistry, that is a more existential theme than any single quarter's margin.
The cash story, at least, is unambiguously improving: free cash flow conversion of 48% on a trailing twelve-month basis, up 9 points, with CapEx normalising toward CHF 150-175 million now that the Daya Bay and flame-retardant capacity build is complete. Savings are at CHF 79 million cumulative of the CHF 100 million target, with roughly 700 positions removed. That is real. The question the market must answer is whether a 48% cash conversion business deserves to be valued on an 18% margin it has not yet delivered, or on the 15.6% it just printed.